Recce Pharmaceuticals (REC) shares surge on positive trial update
Recce Pharmaceuticals (REC) shares surge on positive trial update
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
Recce Pharmaceuticals (REC) shares have marched higher this week on the back of a positive trial update, which revealed its anti infective drug showed a visible reduction in burn wound infections. Recce's trial broad spectrum antibiotics seek to address the problem of drug resistant bacteria. Recce CEO James Graham says Professor Fiona Wood and her team at Fiona Stanley Hospital in Perth are assessing the safety and efficacy of its lead compound R 327 in patients with infected burn wounds under the trial. He says they have reported positive results to date on a small number of patients. James says Recce is very well funded to continue with clinical trials of this and other broad spectrum antibiotics it has in its pipeline of development.
More like this
4:51
Recce strengthens its patent armour14 July 20263:58
Market Update | Oil & Energy Stocks, Gold, Steadfast, Origin Energy, SK Hynix, Ryman Healthcare, Recce, Coronado Global Resources14 July 2026 · GMD, ORG, RYM, SDF52:34
the callthe call: 30th March | RCE ORA DUR VAU SFR 360 KPG IFL WEB SM130 Mar 2026 · 360, IFL, ORA, SFR0:56
Market Update | Pro Medicus, Insurance Australia Group, Credit Corp, Dyno Nobel, Worley, Caterpillar, RPM Global, Genesis Minerals, Virgin Australia, Austal, Bapcor, Harvey Norman, Activeport, Megaport, Recce Pharmaceuticals, 4D Medical1 Sept 2025 · 4DX, ASB, DNL, GMD